GCM
RCUS icon

Graham Capital Management’s Arcus Biosciences RCUS Stock Holding History

Graham Capital Management’s Portfolio RCUS Stock Details RCUS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-13,025
Closed -$102K – 1563
2025
Q1 		$102K Buy
+13,025
New +$151K ﹤0.01% 1210
2022
Q4 		– Sell
-29,867
Closed -$781K – 1293
2022
Q3 		$781K Buy
29,867
+16,474
+123% +$436K 0.03% 586
2022
Q2 		$339K Buy
+13,393
New +$328K 0.01% 786

Other funds holding RCUS

GS
Gilead Sciences Foster City, California $2.12B AUM 143.53% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return
SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $3.61B AUM 203.3% 1-Year Est. Return

Graham Capital Management's RCUS Position: Q2 2025 in Review

Graham Capital Management sold out of Arcus Biosciences (RCUS) in Q2 2025, closing a stake of 13,025 shares — an estimated $102K sold.

Graham Capital Management first reported a position in RCUS in Q2 2022 and held it in 3 quarters. The position peaked at $781K in Q3 2022. 185 funds tracked by Wall St. Rank hold RCUS as of Q2 2025.

  • Graham Capital Management reported no remaining Arcus Biosciences position as of Q2 2025 after selling out during the quarter.
  • Graham Capital Management sold 13,025 Arcus Biosciences shares in Q2 2025, an estimated $102K.
  • Graham Capital Management first reported a position in Arcus Biosciences in Q2 2022 and held it in 3 quarters.
  • Graham Capital Management's Arcus Biosciences position peaked at $781K in Q3 2022.
  • 185 funds tracked by Wall St. Rank held Arcus Biosciences as of Q2 2025.

Based on Graham Capital Management's 13F filing for Q2 2025, filed 14 Aug 2025.